When Antivirals Backfire: An Evaluation of Favipiravir’s Clinical Outcomes in Critically Ill Patients with COVID-19: A Multicenter Cohort Study
Khalid Al Sulaiman, Ohoud Aljuhani, Ghazwa B Korayem, Ali F Altebainawi, Mashael Alfaifi, Majed Nahari, Alaa Almagthali, Abrar K Thabit, Raghad Alhajaji, Reham Alharbi, Khawla Kahtani, Abeer A Alenazi, Aisha Alharbi, Munirah M Alghwainm, Sara M Alotaibi, Yazeed S Alghamdi, Samar Alotaibi, Shaden H Alonazi, Jumanah M Almutairi, Ramesh Vishwakarma
Journal of Infection and Public Health, doi:10.1016/j.jiph.2023.06.011
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Author Contributions All authors agreed to be fully accountable for ensuring the integrity and accuracy of the work and read and approved the final manuscript.
Ethical Approval and Informed Consent Statement The study protocol was reviewed and approved by the Institutional Review Board of King
J o u r n a l P r e -p r o o f
Conflicts of interest The authors declare no conflict of interest.
Declaration of Competing Interest We have no conflict of interest to declare. J o u r n a l P r e -p r o o f
References
Al-Muhsen, Ns, Sharif-Askari, Basamh, Alyounes et al., Favipiravir Effectiveness and Safety in Hospitalized Moderate-Severe COVID-19 Patients: Observational Prospective Multicenter Investigation in Saudi Arabia, Front Med,
doi:10.3389/fmed.2022.826247Alamer, Alrashed, Alfaifi, Alosaimi, Alhassar et al., Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: a retrospective study with propensity score matching sensitivity analysis, Curr Med Res Opin,
doi:10.1080/03007995.2021.1920900Alhazzani, Alshahrani, Alshamsi, Aljuhani, Eljaaly et al., The Saudi Critical Care Society practice guidelines on the management of COVID-19 in the ICU: Therapy section, J Infect Public Health,
doi:10.1016/j.jiph.2021.10.005Aljuhani, Sulaiman, Alshabasy, Eljaaly, Shaya et al., Association between tocilizumab and emerging multidrug-resistant organisms in critically ill patients with COVID-19: A multicenter, retrospective cohort study, BMC Infect Dis J o u r n a l P r e -p r o o f,
doi:10.1186/s12879-021-06813-1Arabia, Saudi MoH Protocol for Adults Patients Suspected of / Confirmed with COVID-19 Supportive care and antiviral treatment of suspected or confirmed COVID-19 infection
Ford, Vitoria, Rangaraj, Norris, Calmy et al., Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19: initial assessment, J Int AIDS Soc,
doi:10.1002/jia2.25489Furuta, Komeno, Nakamura, Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase, Proc Japan Acad Ser B Phys Biol Sci,
doi:10.2183/pjab.93.027Furuta, Takahashi, Shiraki, Sakamoto, Smee et al., T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral J, Antiviral Res,
doi:10.1016/j.antiviral.2009.02.198Guner, Hasanoglu, Kayaaslan, Aypak, Akinci et al., Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir, J Infect Public Health,
doi:10.1016/j.jiph.2020.12.017Harbi, Kensara, Aljuhani, Korayem, Altebainawi et al., Statins and Risk of Thrombosis in Critically ill Patients with COVID-19: A Multicenter Cohort Study, Clin Appl Thromb,
doi:10.1177/10760296221103864Hassanipour, Arab-Zozani, Amani, Heidarzad, Fathalipour et al., The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials, Sci Rep,
doi:10.1038/s41598-021-90551-6Helmy, Fawzy, Elaswad, Sobieh, Kenney et al., The COVID-19 pandemic: A comprehensive review of taxonomy, genetics, epidemiology, diagnosis, treatment, and control, J Clin Med,
doi:10.3390/jcm9041225Irie, Nakagawa, Fujita, Tamura, Eto et al., Population pharmacokinetics of favipiravir in patients with COVID-19, CPT Pharmacometrics Syst Pharmacol,
doi:10.1002/psp4.12685Jang, Jeon, Kim, Sy, Drugs repurposed for COVID-19 by virtual screening of 6,218 drugs and cell-based assay, Proc Natl Acad Sci U S A,
doi:10.1073/pnas.2024302118Lan, Lai, Chang, Lu, Hung et al., Favipiravir-based treatment for outcomes of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials, Expert Rev Clin Pharmacol,
doi:10.1080/17512433.2022.2078701Manabe, Kambayashi, Akatsu, Kudo, Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis, BMC Infect Dis,
doi:10.1186/s12879-021-06164-xMunir, Kuganda, Basry, The efficacy and safety of antivirus drugs for COVID-19: A systematic review, Syst Rev Pharm,
doi:10.31838/srp.2020.7.26Qomara, Primanissa, Amalia, Purwadi, Zakiyah, Effectiveness of remdesivir, lopinavir/ritonavir, and favipiravir for COVID-19 treatment: A systematic review, Int J Gen Med,
doi:10.2147/IJGM.S332458Scape, Saudi, None, Critical Care Pharmacy Research
Solaymani-Dodaran, Ghanei, Bagheri, Qazvini, Vahedi et al., Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia, Int Immunopharmacol,
doi:10.1016/j.intimp.2021.107522Sulaiman, Aljuhani, Eljaaly, Alharbi, Shabasy et al., Clinical features and outcomes of critically ill patients with coronavirus disease 2019 (COVID-19): A multicenter cohort study, Int J Infect Dis,
doi:10.1016/j.ijid.2021.02.037Sulaiman, Aljuhani, Korayem, Hafiz, Alalawi et al., Standard dosing of enoxaparin versus unfractionated heparin in critically ill patient with COVID-19: a multicenter propensity-score matched study, Thromb J,
doi:10.1186/s12959-022-00432-9Sulaiman, Aljuhani, Shaya, Kharbosh, Kensara et al., Evaluation of zinc sulfate as an adjunctive therapy in COVID-19 critically ill patients: a two center propensity-score matched study, Crit Care,
doi:10.1186/s13054-021-03785-1Sulaiman, Korayem, Altebainawi, Harbi, Alharthi, Evaluation of inhaled nitric oxide (iNO) treatment for moderate-to-severe ARDS in critically ill patients with COVID-19: a multicenter cohort study, Crit Care,
doi:10.1186/s13054-022-04158-yWang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res,
doi:10.1038/s41422-020-0282-0Wang, Paulson, Pease, Watson, Comfort et al., Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, Lancet,
doi:10.1016/S0140-6736(21)02796-3Wang, Zhong, Salam, Tarning, Zhan et al., Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza, J o u r n a l P r e -p r o o f Total Bilirubin,
doi:10.1016/j.ebiom.2020.103125Yang, Zeng, Dai, Chen, Yang, A systematic review and Bayesian network meta-analysis for comparative safety assessment of favipiravir interventions in hospitalized COVID-19 patients, J Infect Dev Ctries,
doi:10.3855/jidc.16083Özlüşen, Kozan, Akcan, Kalender, Yaprak et al., Effectiveness of J o u r n a l P r e -p r o o f favipiravir in COVID-19: a live systematic review, Eur J Clin Microbiol Infect Dis,
doi:10.1007/s10096-021-04307-1
